Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors - Trial NCT06418061
Access comprehensive clinical trial information for NCT06418061 through Pure Global AI's free database. This Phase 1 trial is sponsored by Innovent Biologics (Suzhou) Co. Ltd. and is currently Not yet recruiting. The study focuses on Solid Tumors. Target enrollment is 198 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Innovent Biologics (Suzhou) Co. Ltd.
Timeline & Enrollment
Phase 1
Jun 30, 2024
Jun 30, 2027
Primary Outcome
Number of subjects with adverse events,Number of subjects with clinically significant changes in physical examination results,Number of subjects with clinically significant changes in vital signs,Dose limiting toxicities (DLTs)
Summary
The main purpose of this study is to evaluate the safety and tolerability of IBI3005 and to
 determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of
 IBI3005.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06418061
Non-Device Trial